Parkinsonism plus syndrome - A review

Neurology India

Volumn 51, Issue 2, 2003, Pages 183-188

  Mitra, K ^a   Gangopadhaya, P K ^a   Das, Shyamal Kumar ^a  

^a BANGUR INSTITUTE OF NEUROLOGY   (India)

Author keywords

Cortico basal ganglionic degeneration; Dementia with Lewy body disease; Multiple system atrophy; Parkinsonism plus syndromes; Progressive supranuclear palsy

Indexed keywords

ALPHA SYNUCLEIN; AMANTADINE; ANTIPARKINSON AGENT; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; BACLOFEN; BOTULINUM TOXIN; CENTRAL NERVOUS SYSTEM AGENTS; CLONAZEPAM; CYTOKINE; DINUCLEOTIDE; DOPA; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MARKER; NEUROLEPTIC AGENT; QUETIAPINE; TAU PROTEIN;

ACANTHOCYTOSIS; AKINESIA; APRAXIA; AUTONOMIC DYSFUNCTION; BODY POSTURE; BRADYKINESIA; BRAIN CALCIFICATION; BRAIN DEGENERATION; BRAIN SCINTISCANNING; CEREBELLUM DISEASE; CHROMOSOME 14; CHROMOSOME 17; CLINICAL FEATURE; COGNITIVE DEFECT; CORTICOBASAL DEGENERATION; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE EXACERBATION; DRUG EFFECT; DYSTONIA; GAZE PARALYSIS; GLOBUS PALLIDUS; HUMAN; HUMAN EXPERIMENT; HUNTINGTON CHOREA; IDIOPATHIC DISEASE; MYOCLONUS; NEUROLOGIC DISEASE; NIEMANN PICK DISEASE; PAIN; PARKINSON DISEASE; PARKINSONISM PLUS SYNDROME; PHENOTYPE; PHYSIOTHERAPIST; PROGRESSIVE SUPRANUCLEAR PALSY; PYRAMIDAL SIGN; REVIEW; RIGIDITY; SHY DRAGER SYNDROME; TAUOPATHY; TREMOR; WILSON DISEASE;

HUMANS; LEWY BODY DISEASE; MULTIPLE SYSTEM ATROPHY; NEURODEGENERATIVE DISEASES; PARKINSONIAN DISORDERS; SUPRANUCLEAR PALSY, PROGRESSIVE; SYNDROME;

EID: 0242610482     PISSN: 00283886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Jankovic J. Parkinsonism - Plus syndromes. Mov Disord 1989;4:95-119
2. Hu MJ, Bland J. Limb contracture in dopa-responsive Parkinsonism. J Neurol 1999;246:671-6.
3. Stacy M, Jankovic J. Differential diagnosis of Parkinson's disease and the Parkinsonism plus syndromes. Neurol Clinic 1992;10:341-59.
4. Wszolek ZK, Pfeiffer RF. Heredo-familial Parkinsonian syndromes. In: Watts RL, Koller WC, editors. Movement Disorders: Neurologic Principles and Practice. New York: McGraw Hill. 1996:351-63
5. Foster NL, Withelmsen K, Sima AF, et al. Fronto temporal dementia and Parkinsonism linked to chromosome 17: A consensus. Ann Neurol 1997;41:706-15
6. Feany MB, Dickson DW. Neurodegenerative disorders with extensive tau pathology: A comparative study and review. Ann Neurol 1996;40:139-48
7. Brown J, Lantos PL, Rogues P, et al. Familial dementia with swollen achromatic neurons and cortical basal inclusion bodies: A clinical and pathological study. J Neurol Sci 1996;135:21-30.
8. Tsuboi Y, Wszolek ZK, Kushura T, Doh-Ura K, Yamada T. Japanese family with parkinsonism, depression, weight loss and central hypoventilation. Neurology 2002;58:1025-30.
9. Roy EP, Riggs JE, Martin JD, et al. Familial Parkinsonism, apathy, weight loss, and central hypoventilation: Successful long term management. Neurology 1988;38:637-9.
10. Lee LV, Kupke KG, Gaballar-Gonzaga F, et al. The phenotype of the X-linked dystonia- Parkinsonism syndrome. Medicine 1991;70:179-87.
11. Muller V, Haberhausen G, Wagner T, et al. The X-linked dystonia-Parkinsonian syndrome locus (DYT 3). Genomics 1994;23:114-117.
12. Tanaka H, Endo K, Tsuji S, et al. The gene for hereditary progressive dystonia with marked diurnal fluctuation maps to chromosome 14q. Ann Neurol 1995;37:405-8.
13. Brown J, Lantas P, Stratton M, et al. Familial progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1993;56:473-6.
14. De Yebenes JG, Sarasa JL, Daniel SE, et al. Familial PSP: Description of a pedigree and review of literature. Brain 1995;118:1095-103.
15. Spellman GG. Report of familial cases of Parkinsonism. JAMA 1962;79:160-2.
16. Muenter MD, Howard FM Jr, Okazaki H. A familial Parkinson-dementia syndrome. Neurology 1986;36:115-20.
17. Sage J, Miller DC, Golbe LI, et al. Clinically atypical expression of pathologically typical Lewy Body Parkinsonism. Clin Neuropharmacol 1990;13:36-47.
18. MarkoPoulou K. Olfactory dysfunction in familial Parkinsonism. Neurology 1997;49:1262-7.
19. Lopez OL, Litvan I, Catt KE, et al. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementia. Neurology 1999;53:1292-3.
20. Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of MSA. American Autonomic Society and American Academy of Neurology. 1998;8:359-62.
21. Bussiere T, Hoff PR, Mailliot C, et al. Phosphorylated serine on tau protein is a pathological epitope found in several diseases with neurofibrillary degeneration. Acta Neuropathol 1999;97:221-30.
22. Matsusaka H, Ikeda K, Akiyama H, et al. Astrocytioc pathology in PSP Acta Neuropathol 1998;96:248-52.
23. Litvan I, Hutton M. Clinical and genetic aspects of PSP. J Geriatr Psychiatry Neurol 1998;11:107-14.
24. Aguado F, Ballabriga J, Pozas E, et al. Trk A immunoactivity in reactive astrocytes in human neurodegenerative disease and colchicine- treated rats. Acta Neuropathol 1998;96:495-501.
25. Hutton M, Leudon CL, Rizza P, et al. Association of mutation in tau with inherited dementia FTDP-17. Nature 1998;393:702-5.
26. Hanna PA, Jankovic J, Kirkpatrick JB. MSA: Putative causative role of environmental toxins. Arch Neurol 1999;56:90-4.
27. Benarroch EE, Smithson IL, Low PA, et al. Depletion of noradrenergic neurons of medulla in MSA with autonomic failure. Ann Neurol 1998;43:156-63.
28. Schulz JB, Skalej M, Wedebind D, et al. MRI volumetry differentiates IPD from MSA and PSP. Ann Neurol 1999;45:65-74.
29. Hierholzer J. Cerebral SPECT with iodine 123 IBZM in patients with extrapyramidal system disorders. La Radiologia Medica 1996;91:207-10.
30. Tissingh G. IBZM and CIT-SPECT of the dopaminergic system in Parkinsonism. J Neural Transm Suppl 1997;50:31-7.
31. Steel JC, Richardson JC, Olszewski J: Progressive supranuclear palsy. Arch Neurol. 1964;10:333-59.
32. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy. Report of NINDS-SPSP International workshop Neurology 1996;46:922-30.
33. Arouti A, SchmidtZ K, Lyons KE, et al. Normal distribution of apolipoprotein E alleles in progressive supranuclear palsy. Neurology 1996;46:156-1157.
34. Stern MB, Braffman EM, Skolnick BE. et al. MRI in Parkinson's disease and Parkinsonian syndrome. Neurology 1989;39:1524-5.
35. Blin J, Baron JC, Dubois B, et al. PET in PSP. Arch Neurol 1990;47:747-52.
36. Litvan I, Sastry N, Sonies BC. Characteristic swallowing abnormalities in PSP. Neurology 1997;48:1654-60.
37. Cubo E, Steffins GT, Golbe LI, et al. Application of unified Parkinson's disease scale in progressive supranuclear palsy. Movement Disorders 2000;15:276-9.
38. Quinn N. Multiple system atrophy. In: Marsden CD, Fahn S, eds. Movement Disorders 3. Oxford: Butterworth-Heinmann Ltd; 1994:262-81.
39. Papp MI, Lantos PL. The distribution of oligodendronglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 1994;117:235-43.
40. Rascol O, Sabatini K, Fabre N, et al. Abnormal VOR cancellation in MSA and PSP but not in PD. Movement Disorders 1995;10:163-70.
41. Barbiroli B, Martinelli P, Patuelli A, et al. Phosphorus MR Spectroscopy in MSA and PD. Movement Disorder 1999;14:430-5.
42. Stocchi F, Badiali D, Vacca L, et al. Anorectal function in MSA and PD Movement Disorders. 2000;15:71-6.
43. Abele M, Schulz JB, B Ürk K, et al. Evoked potentials in MSA. Acta Neurol 2000;101:111-5.
44. Shafiq M, Lang AE. Myoclonus in Parkinsonian disorders. Advances in Neurology 2002;89:77:83.
45. Thompson PD, Day BL, Rothwell JC, et al. The myoclonus in Cortico-basal degeneration evidence for two forms of cortical myoclonus. Brain 1994;117:197-1267.
46. Gibb WRG, Luther PJ, Marsden CD. Clinical and pathologic features of CBD. Adv Neurol 1990;53:51-3.
47. Nagahama Y, Fukuyama H, Turjanski N, et al. Cerebral glucose metabolism in CBGD. Movement Disord 1997;12:691-6.
48. Leigurda R, Lees AJ, Merello, et al. The nature of apraxia in CBD. J Neurol Neurosurg Psychiat 1994;57:455-9.
49. Rey GJ, Tomer R, Levin BE, et al. Psychiatry symptom, atypical dementia and left visual field inattention in CBGD. Movement Disorders 1995;10:106-10.
50. Quinlan RA, Nicholl ID. Chaperone activity of alpha crystalline modulates intermediate filament assembly. EMBO J 1994;13:948-53.
51. Jendroska K, Rossor MN, Mathias CJ, et al. Morphologic overlap between CBD and Pick disease: A clinico pathologic report. Movement Disorders 1995;10:111-4.
52. Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease. Neurology 1996;47:148-52.
53. McKeith IG, Galasko D, Kosaka K, et al. Clinical and pathological diagnosis of dementia with Lewy Bodies (DLB): Report of the CDLB international workshop Neurology 1996;47:1113-24.
54. Jellinger KA. Rare neurodegenerative disorders In: Calne DB, editor. Neurodegenerative Diseases. Philadelphia: WB Saunders; 1994. pp. 909-931
55. Comella CL. Bilateral striato pallido dentate calciuosis In: Stern MB, Koller WC, eds. Parkinsonian Syndromes. New York: Marcel Dekkar; 1993. pp. 483-501.
56. Yamamoto T, Hirosa G, Shimazaji K, et al. Movement disorders of familial neuroacanthocytosis syndromes. Arch Neurol 1982;39:298-301.
57. Peppard RF, Lue CS, Chu NS, et al. Parkinsonism with neuroacanthocytosis. Can J Neurol Sci. 1990;17:298-301.
58. Elison D, Love S. Parkinsonism and akinetic-rigid disorders. In: David Elison, Seth love, eds. Neuropathology - A Reference Text of CNS Pathology. London: Mosby International, 1998. 28. pp. 1-28.